Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02313376 · ClinicalTrials.gov registry record · Phase 1
Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes
A Phase 1 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02313376 is a Phase 1 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 10 participants.
The verdict
NCT02313376, a Phase 1 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Study designed to evaluate safety and tolerability of a genetically attenuated P. falciparum (GAP3KO) that arrests early in the liver stage of the parasite life cycle. Study will also confirm the attenuation of the GAP3KO parasites using peripheral blood smears. Secondary objectives are to evaluate the humoral immune responses to GAP3KO.
Interventions
- BIOLOGICAL GAP3KO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02313376
The ClinicalTrials.gov registry entry for NCT02313376 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GAP3KO is the first listed.
NCT02313376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02313376 about?
NCT02313376 is a clinical study titled "Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes". Study designed to evaluate safety and tolerability of a genetically attenuated P. falciparum (GAP3KO) that arrests early in the liver stage of the parasite life cycle. Study will also confirm the attenuation of the GAP3KO parasites using peripheral blood smears. Secondary objectives are to evaluate ...
What is the current status of trial NCT02313376?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-12. Estimated completion is 2015-08.
What interventions are being tested in trial NCT02313376?
The interventions under investigation include: GAP3KO (BIOLOGICAL).
Who is sponsoring clinical trial NCT02313376?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.